NeoGraph Analytics
Life SciencesGlobal2026 – 2032

Liquid Biopsy Market Size, Share & Forecast 2026-2032

Liquid biopsy estimates spread 4.36x at the same base year and 2.55x on growth. A per-test test against Guardant's disclosed volumes shows why.

Revenue, 2026

$8.0B

Forecast, 2032

$17.5B

CAGR, 2026-2032

13.91%

Report Coverage

Global

Code: liquid-biopsy-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Published estimates of the liquid biopsy market disagree twice over, and the two disagreements have different causes. At the same 2024 base year, four houses publish $2.21 billion, $6.17 billion, $6.4 billion and $9.63 billion -- a 4.36x spread. Published compound growth rates run from 9.0% to 28.61%, a 2.55x spread. In the oncology information systems market the rates agree and only the base years diverge; here nothing agrees, and a reader given a single headline number has been told nothing about the market.

The base-year spread is a scope difference that one source states openly: Towards Healthcare labels its $2.21 billion figure as liquid biopsy in-vitro diagnostics -- kits, assays and instruments. Almost all of the revenue in this field is laboratory service revenue, because the tests that sell are laboratory-developed tests run in CLIA-certified laboratories. Guardant Health alone booked $982.0 million in FY2025. A $2.21 billion whole-market figure cannot be counting that.

The growth-rate spread is a bet, and it can be identified with arithmetic rather than opinion. Guardant's disclosed FY2025 figures give a realised therapy-selection price of $683.6 million over roughly 276,000 oncology tests, or $2,477 per test. Divide Fortune Business Insights' $106.49 billion 2034 forecast by that price and it implies 43.0 million tests a year. GLOBOCAN 2022 puts total new cancer cases worldwide at close to 20 million. The high forecast implies 2.15 liquid biopsies per year for every newly diagnosed cancer patient on earth, which is not therapy selection. It is population screening of asymptomatic people, priced as though reimbursement already existed.

That is the fault line. The low-rate houses are forecasting a market that exists and is paid for. The high-rate houses are forecasting multi-cancer early detection. Before comparing two liquid biopsy forecasts, establish which of those two things each one is counting.

02

Key Highlights

1

Base-year estimates spread 4.36x at the same 2024 year, from $2.21 billion to $9.63 billion

2

Published CAGRs spread 2.55x, from 11.21% to 28.61% -- so unlike most markets, the growth rate is contested too

3

Guardant Health's disclosed FY2025 figures give $2,477 per therapy-selection test and $916 per screening test

4

Fortune Business Insights' $106.49 billion 2034 forecast implies 43.0 million tests a year, 2.15x global annual cancer incidence

5

That arithmetic rules out a therapy-selection reading of the high forecasts: they assume population screening

6

Revenue here is laboratory service revenue, not product revenue, which is why product-scope estimates land near $2 billion

7

No vendor discloses market share, and the two circulating regional splits are nine points apart

03

Market Overview

Market Context

A liquid biopsy looks for tumour material -- circulating tumour DNA, circulating tumour cells, exosomes, methylation signatures -- in a blood draw instead of a tissue sample. Its established clinical job is narrow and valuable: genotyping an advanced solid tumour when tissue is insufficient, inaccessible or stale, so that a targeted therapy can be chosen. The FDA approved the first two companion diagnostics on that indication within three weeks of each other in August 2020, Guardant360 CDx on 7 August and FoundationOne Liquid CDx on 26 August. The commercial structure follows from the regulation. Because a laboratory-developed test run in a CLIA-certified laboratory is a service rather than a distributed product, the money in this field shows up as service revenue priced per test by payers, not as instrument and reagent sales. CMS set Guardant360's rate at $5,000 for code 0326U effective 1 January 2024. That single administrative decision does more to determine the size of this market than any technical advance in the same period. The second market -- screening asymptomatic people for cancer they do not know they have -- is governed by entirely different economics. Guardant's Shield screening test was priced at $920 by Medicare from 1 August 2024 and later $1,495 under ADLT status, roughly a fifth to a third of the therapy-selection rate, because screening only works at population scale and population scale only works at low unit cost. Conflating the two markets is the single most common error in the published literature on this category.

On the therapy-selection definition used by the most recently based published series, the liquid biopsy market is $8.03 billion in 2026, projected to $17.54 billion by 2032 at a 13.91% CAGR. Published estimates spread 4.36x at the same 2024 base year and 2.55x on growth rate. The base-year spread is a scope difference between in-vitro-diagnostic product revenue and laboratory service revenue; the growth-rate spread is a disagreement about whether multi-cancer early detection screening becomes a reimbursed activity before the forecast ends. Those are two markets, not one market growing at uncertain speed.

Market Stage

Growth

Adoption Level

Established in advanced solid tumour genotyping; pre-reimbursement in screening

Key Trends

Base-year estimates spread 4.36x at the same 2024 year ($2.21B to $9.63B) and published CAGRs spread 2.55x (11.21% to 28.61%)The low-rate houses are forecasting therapy selection; the high-rate houses are forecasting population screening, which is a different market with a fifth of the unit priceFortune Business Insights' $106.49B 2034 forecast implies 43.0 million tests a year at Guardant's disclosed $2,477 ASP, against close to 20 million new cancers worldwide per GLOBOCAN 2022Revenue in this field is laboratory service revenue, not product revenue, because the tests that sell are laboratory-developed tests run in CLIA-certified laboratoriesReimbursement decisions move the market more than technology: CMS set Guardant360's rate at $5,000 for code 0326U effective 1 January 2024 and Shield at $920 from 1 August 2024Vendor market share is not publicly disclosed by any company or named source in this category
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 13.91%

Base Year (2026)

$8.0B

Forecast (2032)

$17.5B

CAGR (2026-2032)

13.91%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$8.03B
2027$9.15B
2028$10.42B
2029$11.87B
2030$13.52B
2031$15.40B
2032$17.54B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR between published endpoints. How these figures are produced.
Forecast Analysis

The curve shown here is modelled at a constant 13.91% rate. Precedence Research publishes $7.05 billion for 2025 and a stated 13.91% CAGR over 2025-2034; the 2026 base of $8.03 billion is that published figure advanced one year at that published rate, and the 2032 endpoint of $17.54 billion continues it. The intermediate years are interpolation, not separately sourced observations, and should be read as the shape the two endpoints imply. This series was chosen for three reasons. It carries an explicit base-year value and an explicit rate, where several houses publish only an endpoint. Its rate sits inside the therapy-selection cluster of 11.2% to 13.9%, which is the activity that is clinically established and reimbursed today. And it survives the per-test plausibility test described in the executive summary, where the 25.9% and 28.61% series do not. Readers modelling the screening case should not use this curve. They should take a view on whether multi-cancer early detection achieves broad reimbursement before 2032, because that single question, not the growth of genotyping, is what separates a $17 billion market in 2032 from a $100 billion one in 2034. At Guardant's disclosed screening price of $916 per test, a $106.49 billion market implies 116 million screening tests a year, more than the entire screening-eligible population of the United States and European Union combined.

05

Market Dynamics

  • Targeted therapies that require a specific molecular alteration before they can be prescribed, which makes genotyping a gate on the prescription rather than an optional test
  • Tissue insufficiency: a meaningful share of advanced solid tumour patients cannot supply an adequate biopsy, and blood is the only available route
  • Established Medicare pricing for the leading tests, which converts clinical utility into realisable revenue
  • Companion diagnostic approvals that tie a test to a specific drug label, creating demand that follows the drug's uptake rather than diagnostic fashion
  • Minimal residual disease and recurrence monitoring, which turns a single diagnostic event into a repeated longitudinal one
06

Market Segmentation

By Type

  • Circulating tumour DNA (ctDNA) assays
  • Circulating tumour cell (CTC) assays
  • Exosome and extracellular vesicle assays
  • Methylation and fragmentomic signature assays

By End User

  • Reference and specialty laboratories
  • Hospitals and academic medical centres
  • Pharmaceutical and biotechnology companies
  • Community oncology practices

By Application

  • Therapy selection in advanced solid tumours
  • Resistance mutation monitoring
  • Minimal residual disease and recurrence monitoring
  • Multi-cancer early detection screening
  • Clinical trial enrolment and biopharma research
07

Competitive Landscape

G

Guardant Health

United States

Incumbent in therapy-selection testing; the only pure-play with disclosed test volumes

Reported $982.0 million of FY2025 revenue, of which $683.6 million was oncology on roughly 276,000 tests and $79.7 million was screening on roughly 87,000 Shield tests. Guardant360 CDx was the first FDA-approved liquid biopsy companion diagnostic, on 7 August 2020, and was approved in June 2026 as a companion diagnostic for zongertinib in HER2-mutant advanced NSCLC. Guardant reports 25 companion-diagnostic indications, a count of indications rather than of share. No market share percentage is publicly disclosed.

F

Foundation Medicine (Roche)

United States / Switzerland

Incumbent, reached from comprehensive tissue genomic profiling

FoundationOne Liquid CDx was approved by the FDA on 26 August 2020 and covers more than 300 genes, with companion indications that have accumulated across ovarian, breast, prostate and non-small cell lung cancer. Revenue is consolidated within Roche Diagnostics and is not separately disclosed, so neither its size nor its share can be stated.

N

Natera

United States

Challenger, strongest in molecular residual disease rather than therapy selection

Approaches the category from reproductive and transplant genetics and has built its oncology position on personalised, tumour-informed residual disease testing rather than on companion diagnostics. Liquid biopsy revenue is not broken out as a separate reported segment, and no share figure is public.

E

Exact Sciences

United States

Challenger in screening; ownership changing

Built on stool-based colorectal screening rather than blood, and extending into blood-based screening and residual disease. Abbott announced an agreement to acquire the company in its full-year 2025 results of 22 January 2026 and said it expected the transaction to close in the second quarter of 2026, which would place a large screening franchise inside a diagnostics major. No liquid biopsy share figure is public.

08

Recent Developments

26
2026Guardant Health

Guardant360 CDx approved by the FDA as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib) in HER2-mutant advanced non-small cell lung cancer, announced 10 June 2026.

26
2026Abbott / Exact Sciences

Abbott announced an agreement to acquire Exact Sciences in its fourth-quarter and full-year 2025 results of 22 January 2026, stating that it expected the transaction to close in the second quarter of 2026.

26
2026Guardant Health

Reported FY2025 revenue of $982.0 million, up 33%, including $79.7 million of Shield screening revenue on approximately 87,000 tests, and guided 2026 revenue to $1.25-1.28 billion (19 February 2026).

09

Regulatory Landscape

FDA premarket approval (PMA) for companion diagnostics: Guardant360 CDx approved 7 August 2020 and FoundationOne Liquid CDx approved 26 August 2020, each tied to specific drug labels rather than to a general diagnostic claimCLIA certification under 42 CFR Part 493, which governs the laboratories that run the laboratory-developed tests carrying most of this market's revenueCMS Clinical Laboratory Fee Schedule and the PAMA framework, which set the per-test rates that determine realisable revenue: $5,000 for code 0326U from 1 January 2024Advanced Diagnostic Laboratory Test (ADLT) status, which sets an initial price from list and then resets it to the median private payer rate, as applied to Shield at $920 and subsequently $1,495EU In Vitro Diagnostic Regulation (IVDR) 2017/746, which reclassified most cancer-related assays upward and requires notified body conformity assessment
10

Research Methodology

Primary research

  • No primary interviews were conducted for this edition. This report is a synthesis of public filings, public registers and published third-party estimates, and is labelled as such rather than implying fieldwork that did not occur.

Secondary research

  • Guardant Health, fourth-quarter and full-year 2025 results (19 February 2026) and Form 10-K for FY2025, SEC EDGAR CIK 1576280: $982.0M total revenue, $683.6M oncology on ~276,000 tests, $79.7M screening on ~87,000 Shield tests
  • Bray F. et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin (2024): close to 20 million new cancer cases worldwide
  • ClinicalTrials.gov API v2, query.term='liquid biopsy', retrieved 16 October 2026: 860 registered studies against 607,160 studies in the register
  • FDA premarket approval records and contemporaneous coverage for Guardant360 CDx (7 August 2020) and FoundationOne Liquid CDx (26 August 2020)
  • CMS Clinical Laboratory Fee Schedule determinations reported by 360Dx and GenomeWeb: $5,000 for code 0326U effective 1 January 2024; Shield at $920 effective 1 August 2024 and $1,495 under ADLT
  • Published market estimates from Precedence Research (2025), Fortune Business Insights, MarketsandMarkets, Towards Healthcare, Spherical Insights (15 November 2023), SkyQuest Technology (2024) and Data Bridge Market Research
  • Abbott Laboratories, fourth-quarter and full-year 2025 results, 22 January 2026, and Form 10-K for FY2025

Validation: Market size is taken from published third-party estimates and attributed to each house by name; no methodology behind those estimates was inspected, and they are presented as published estimates rather than as verified measurements. The per-test figures in this report are a plausibility test: $683.6 million of Guardant Health oncology revenue divided by approximately 276,000 oncology tests gives $2,477, and dividing published market sizes by that price gives an implied annual test volume which is then compared with GLOBOCAN 2022 global cancer incidence of close to 20 million cases. That test shows the 25.9% and 28.61% series cannot describe therapy-selection testing, because they imply more tests per year than there are cancer diagnoses; it does not establish what the correct market size is and is not offered as an estimate. The divisor is one company's realised average selling price in one year, not an industry average, and realised prices outside the United States are materially lower. The 2026 base value is Precedence Research's published 2025 figure advanced one year at Precedence's own published rate, not a separately published observation.

11

Strategic Takeaways

Before comparing two liquid biopsy forecasts, establish whether each one is counting therapy selection or population screening, because that decision moves the 2034 endpoint by more than 12x

Treat a product-scope figure near $2 billion and a service-scope figure near $9 billion as answers to different questions, not as a disagreement

Model the screening case as a reimbursement question, not a technology question

at the disclosed $916 screening price the high forecast needs 116 million tests a year

Treat any liquid biopsy vendor share percentage you are shown as unsourced, because no company in this category discloses one

Watch the CLFS and ADLT rate-setting calendar more closely than the assay pipeline, since a single code determination moves realisable revenue more than most technical advances

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.